DNV001 Injection in Patients With Hypercholesterolemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

Also called NCT07391722

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Hangzhou Dinovate Biotech Co., Ltd (from the registry)
Registry
  • NCT NCT07391722
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07391722. Randomized; quadruple masking; primary purpose treatment. Start 2026-02-05 (anticipated); primary completion 2027-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
DNV001 Injection in Patients With Hypercholesterolemia
Acronym
DNV001
Condition
Primary Hypercholesterolemia
Intervention (Biological)
DNV001 Injection
Intervention (Biological)
Placebo
Lead sponsor
Hangzhou Dinovate Biotech Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct07391722
Content hash
34b89ca1697395522627f310a8d188d2417fe12c28b5b44bfadf0faf30a315c8